Literature DB >> 28105105

Silencing of hypoxia-inducible factor-1α promotes thyroid cancer cell apoptosis and inhibits invasion by downregulating WWP2, WWP9, VEGF and VEGFR2.

Zhong-Yang Ding1, Yun-Juan Huang2, Jian-Dong Tang1, Gan Li1, Pan-Qiang Jiang1, Hao-Tian Wu1.   

Abstract

Adaptation to hypoxia is an important process physiologically and pathologically. Hypoxia-inducible factor-1α (HIF-1α) participates in the cancer biology of numerous endocrine tumors, including their proliferation and differentiation. In the present study, the hypothesis that HIF-1α promotes tumorigenesis in thyroid cancer via upregulating angiogenesis-associated markers is investigated. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis were used to examine the expression of HIF-1α in thyroid cancer cell lines, and to detect the expression of WW domain containing E3 ubiquitin protein ligase (WWP)2, WWP9, vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2) in MZ-CRC-1 and TT thyroid cancer cells. Cell proliferation was measured using a Cell Count Kit-8. Cell apoptosis and cell cycle was assessed by flow cytometry. Cell invasive ability was examined by Matrigel transwell analysis. RT-qPCR and western blot analyses demonstrated that the mRNA and protein expression levels of HIF-1α were significant higher in MZ-CRC-1 and TT thyroid cancer cells than in another three thyroid cancer cells (P<0.01). HIF-1α knockdown cells demonstrated inhibition of cell proliferation and invasion, arrested cell cycle at the G1 phase, and induction of cell apoptosis. The protein expression levels of WWP2, WWP9, VEGF and VEGFR2 were decreased in HIF-1α knockdown MZ-CRC-1 and TT cells. In conclusion, HIF-1α may be important in cell apoptosis and invasion of thyroid cancer cells, likely through regulating WWP2, WWP9, VEGF and VEGFR2 expression.

Entities:  

Keywords:  angiogenesis; hypoxia; hypoxia-inducible factor-1α; invasion; thyroid cancer

Year:  2016        PMID: 28105105      PMCID: PMC5228437          DOI: 10.3892/etm.2016.3826

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  30 in total

Review 1.  Hypoxia signalling in cancer and approaches to enforce tumour regression.

Authors:  Jacques Pouysségur; Frédéric Dayan; Nathalie M Mazure
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

Review 2.  VEGF as a key mediator of angiogenesis in cancer.

Authors:  Peter Carmeliet
Journal:  Oncology       Date:  2005-11-21       Impact factor: 2.935

Review 3.  The role of hypoxia-induced factors in tumor progression.

Authors:  Peter Vaupel
Journal:  Oncologist       Date:  2004

4.  Rapamycin decreases survivin expression to induce NSCLC cell apoptosis under hypoxia through inhibiting HIF-1α induction.

Authors:  Bin Chen; Sun Yuping; Jian Ni
Journal:  Mol Biol Rep       Date:  2011-05-13       Impact factor: 2.316

5.  Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer.

Authors:  M M Vleugel; A E Greijer; A Shvarts; P van der Groep; M van Berkel; Y Aarbodem; H van Tinteren; A L Harris; P J van Diest; E van der Wall
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

Review 6.  The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis.

Authors:  A John; G Tuszynski
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

7.  Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma.

Authors:  Q C Yang; B F Zeng; Z M Shi; Y Dong; Z M Jiang; J Huang; Y M Lv; C X Yang; Y W Liu
Journal:  J Exp Clin Cancer Res       Date:  2006-12

8.  Hypoxia inducible factor-1 alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma.

Authors:  M Ioannou; R Papamichali; E Kouvaras; I Mylonis; D Vageli; T Kerenidou; S Barbanis; A Daponte; G Simos; K Gourgoulianis; G K Koukoulis
Journal:  Lung       Date:  2009-08-26       Impact factor: 2.584

9.  A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns].

Authors:  S A Hundahl; I D Fleming; A M Fremgen; H R Menck
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

10.  Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas.

Authors:  N Burrows; J Resch; R L Cowen; R von Wasielewski; C Hoang-Vu; C M West; K J Williams; G Brabant
Journal:  Endocr Relat Cancer       Date:  2010-01-29       Impact factor: 5.678

View more
  5 in total

1.  Monocarboxylate transporter 1 (MCT1), a tool to stratify acute myeloid leukemia (AML) patients and a vehicle to kill cancer cells.

Authors:  Filipa Lopes-Coelho; Carolina Nunes; Sofia Gouveia-Fernandes; Rita Rosas; Fernanda Silva; Paula Gameiro; Tânia Carvalho; Maria Gomes da Silva; José Cabeçadas; Sérgio Dias; Luís G Gonçalves; Jacinta Serpa
Journal:  Oncotarget       Date:  2017-08-16

Review 2.  GPCRs in Cancer: Protease-Activated Receptors, Endocytic Adaptors and Signaling.

Authors:  Aleena K S Arakaki; Wen-An Pan; JoAnn Trejo
Journal:  Int J Mol Sci       Date:  2018-06-27       Impact factor: 5.923

Review 3.  Hypoxia in Solid Tumors: How Low Oxygenation Impacts the "Six Rs" of Radiotherapy.

Authors:  Andria Rakotomalala; Alexandre Escande; Alessandro Furlan; Samuel Meignan; Eric Lartigau
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-02       Impact factor: 5.555

Review 4.  Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers.

Authors:  Rita Niciporuka; Jurijs Nazarovs; Arturs Ozolins; Zenons Narbuts; Edvins Miklasevics; Janis Gardovskis
Journal:  Medicina (Kaunas)       Date:  2021-10-19       Impact factor: 2.948

5.  Hyperoxia sensitizes hypoxic HeLa cells to ionizing radiation by downregulating HIF‑1α and VEGF expression.

Authors:  Dan Dong; Yan Fu; Feng Chen; Jing Zhang; Haiyan Jia; Jia Li; Huailin Wang; Jihong Wen
Journal:  Mol Med Rep       Date:  2020-11-20       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.